Conakry

NATURE by Erika Check Hayden                                                                             Aug. 10, 2015
As West Africa’s Ebola outbreak winds down, an effort is under way to make the best use of the tens of thousands of patient samples collected by public-health agencies fighting the epidemic.  Samples from the Ebola epidemic in West Africa are held by public-health agencies in the region and abroad. Daniel Berehulak/NYT/Redux/Eyevine

On 6–7 August, the World Health Organization (WHO) convened a meeting in Freetown, Sierra Leone, to discuss how to establish a biobank for up to 100,000 samples of blood, semen, urine and breast milk from confirmed and suspected Ebola patients, as well as swabs taken from the bodies of people who died from the virus. Held by health agencies in both West Africa and the West, the samples could be valuable in understanding how the current Ebola crisis evolved, preparing for future outbreaks and developing public-health research capacity in a region that depends on outside experts.

PHARMACEUTICAL PROCESSING by  Princeton University, Woodrow Wilson School of Public and International Affairs   Aug. 6, 2015

Ebola is a preventable disease, and yet a safe and effective vaccine has not been deployed. As with many vaccines, financial barriers persist: pharmaceutical companies see high costs with limited market potential, and government support is lacking. But there may be a solution to this vaccine crisis with the ability to save at-risk populations, according to a perspective piece written by physicians based at Princeton University, University of Pennsylvania and the Wellcome Trust.

The article, published in the New England Journal of Medicine, proposes the creation of a $2 billion global vaccine-development fund - supported by governments, foundations and pharmaceutical companies - that would carry promising vaccines through development to deployment. With initial support, the global vaccine fund could help make vaccines available for emergency use.

Analysis
WIRED.COM by Katie M. Palmer                                                            Aug. 4, 2015

Last week, the medical journal the Lancet published preliminary results on the efficacy of an Ebola vaccine in Guinea, and everybody got really excited—especially about one particular figure. The vaccine, the results suggested, was 100 percent effective at protecting against Ebola, a thrilling prospect in the face of an epidemic that has killed more than 11,000 people. ...

But that number probably means less than you think it does. It’s based on incomplete data, so it doesn’t have the statistical clout it should. And it never will. Based on the vaccine’s early success, the trial’s runners decided that all participants in the study should get it immediately after exposure. That’s a perfectly reasonable, humane reaction, but it also means that the researchers will never be able to collect better data on the vaccine’s efficacy, which is what regulators look for when they’re deciding to approve a drug. In other words, the vaccine’s early success could make it harder for people to get it down the line.

The U.S. Government announces it intends to invest more than $1 billion in resources to expand the Global Health Security Agenda to prevent, detect, and respond to future infectious disease outbreaks overseas.

THE WHITE HOUSE PRESS OFFICE                       July 28, 2015

The Ebola epidemic in West Africa continues to galvanize global attention and resources as the international community strives to eliminate active cases and help the affected countries recover.  African leaders and African Union officials have shown extraordinary leadership in addressing the outbreak. The epidemic highlighted the urgent need to establish global capacity to prevent, detect, and respond to biological threats – to prevent future outbreaks from becoming epidemics. 

Beginning with the release of the National Strategy for Countering Biological Threats in 2009, and outlined in his 2011 speech at the United Nations General Assembly, President Obama has called upon all countries to come together to prevent, detect, and respond to infectious disease threats, whether naturally occurring, accidental or deliberately spread.  Today, the President underscored the unwavering U.S. commitment to partnering with Africans, their governments, and all who will join the effort to improve health security across the continent and for all people.